Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01015911 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT01015911 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 58 participants.
The verdict
NCT01015911, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in patients with CD70-positive relapsed or refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
Interventions
- DRUG SGN-75
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2009-11 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01015911
The ClinicalTrials.gov registry entry for NCT01015911 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGN-75 is the first listed.
NCT01015911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01015911 about?
NCT01015911 is a clinical study titled "A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma". This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in patients with CD70-positive relapsed or refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
What is the current status of trial NCT01015911?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2009-11. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01015911?
The interventions under investigation include: SGN-75 (DRUG).
Who is sponsoring clinical trial NCT01015911?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.